

Concept Article

Next-Generation Risk Assessment of Chemicals – Rolling Out a Human-Centric Testing Strategy to Drive 3R Implementation: The RISK-HUNT3R Project Perspective

Giorgia Pallocca^{1*}, Martijn J. Moné^{2*}, Hennicke Kamp³, Mirjam Luijten⁴, Bob van de Water^{2#} and Marcel Leist^{1,5#}

¹CAAT-Europe, University of Konstanz, Konstanz, Germany; ²Cancer Therapeutics and Drug Safety group at the Division of Drug Discovery & Safety, University Leiden, Leiden, The Netherlands; ³BASF Metabolome Solutions GmbH, Berlin, Germany; ⁴RIVM, Bilthoven, The Netherlands;

⁵In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany

Abstract

In many industrial sectors, there is a need for reliable ways to evaluate the safety of chemicals with methods anchored to human biology and pathology. For this purpose, many animal-free new approach methods (NAMs) have been developed and implemented in various stages of risk assessment. Now it is time to assemble individual NAMs into a comprehensive next-generation risk assessment (NGRA) strategy. The European Horizon 2020 RISK-HUNT3R project (Risk assessment of chemicals integrating human-centric next-generation testing strategies promoting the 3Rs) has been designed to promote a combination of computational toxicology, *in vitro* toxicology, and systems biology. It is anticipated that this approach will lead to faster and more accurate risk assessment procedures. The RISK-HUNT3R NGRA strategy will be developed to address the implementation of a comprehensive NAM toolbox into the regulatory framework. Critical conceptual approaches of the project include i) the integration of human-relevant data on biotransformation and elimination, ii) the translation of high-content mode-of-action datasets into predictions of adverse outcomes, iii) development of quantitative adverse outcome pathways (qAOPs), and iv) quantification of uncertainties associated with the predictions based on NGRA strategies. Many of the project steps will be used iteratively to generate datasets with sufficient quality and certainty for NGRA. Scientists and regulators will work together on case studies to evaluate practical applicability of NAMs and strategies to combine information therefrom. Here we delineate how the strategy will be deployed to establish an overall NGRA framework for chemicals, pesticides, food additives, and drugs.

1 Introduction

Safety assessment of chemicals from all industrial sectors has, until recently, almost entirely relied on animal experimentation. As a result, the definition of adversity has been mostly based on so-called apical endpoints that are directly observable (e.g., histopathological changes, morphological defects, and behavioral changes). Shortcomings of this black-box, phenotype-oriented approach include the lack of mechanistic information, problems with interspecies extrapolation due to physiological and genetic

differences between animals and humans, and difficulties in detecting pathologies significant to humans but hard to assess in animals. Another disadvantage of an animal-based risk assessment is the high false-positive rate (Hartung and Leist, 2008). This consideration means that the development of valuable candidate drugs and chemicals may be stopped because of toxicity findings in animals that are not relevant to humans. This is a severe drawback for industry and society (Leist and Hartung, 2013; Ennever and Lave, 2003; Busquet et al., 2020). In situations of time limitation (e.g., for candidate COVID drugs), the lengthiness of animal

*shared first author; #shared last author

Received April 5, 2022;
Epub April 7, 2022; © The Authors, 2022.

ALTEX 39(3), 419–426. doi:10.14573/altex.2204051

Correspondence: Giorgia Pallocca, PhD
CAAT-Europe, University of Konstanz
Universitätsstr. 10, 78457 Konstanz, Germany
(giorgia.pallocca@uni-konstanz.de)

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International license (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited.



	The assessment is...
OBJECTIVES	1. focused on safety
	2. exposure-led
	3. hypothesis-driven
	4. based on adversities (rather than "perturbations")
	The assessment uses...
PROCEDURE	5. consideration of all existing info
	6. tiered and iterative approaches
	7. robust and relevant methods and strategies
	The assessment includes...
DOCUMENTATION	8. documentation and quantification of uncertainty
	9. documentation of all steps and the rationale for conclusions

Fig. 1: Principles of next-generation risk assessment (NGRA) implemented in the RISK-HUNT3R project
NGRA principles have been translated into the RISK-HUNT3R testing framework. Principles are classified into three groups: objectives, procedure, and documentation. In the first group, the four main goals of NGRA are identified; in the second group, considerations on strategies to be used in the assessment are listed. In the third group, elements necessary to provide adequate documentation are explicated.

studies can be a bottleneck. A critical strategic change in toxicology was suggested in a 2007 vision document (NRC, 2007; Leist et al., 2008; Hartung, 2009; Krewski et al., 2020; Weaver et al., 2020) delineating three major focal shifts to transform chemical risk assessment to become i) exposure-led, ii) hypothesis-driven, and iii) NAM-based – altogether firmly setting the stage for NGRA.

Scientific advances in individual NAMs have paved the way for their successful application and integration in chemical safety testing, e.g., for complex endpoints such as skin sensitization. Yet despite the successful integration of various NAMs in the pre-marketing safety assessment of chemicals, remaining challenges for a broad-ranging and successful implementation of animal-free approaches to risk assessment have become more evident. Current limitations have several reasons. Firstly, individual NAMs will not allow a complete hazard assessment for complex endpoints. Although this notion is scientifically evident, a mindset of one-on-one test replacement is still frequently encountered. It has proven difficult to introduce hazard predictions based on a combination of NAM data. Secondly, more and better concepts are needed to set thresholds for human exposure (like acceptable daily intake or tolerable workplace exposure) based on NAM-derived data. Thirdly, while tests have been extensively applied to model acute effects, *in vitro* tests for chronic effects are still challenging due to limited culturing times. Thus, a systematic evaluation of the validity of NAMs for chronic human health impacts is lacking.

Past projects have contributed to developing strategies to solve

the above problems. The Horizon 2020 EU-ToxRisk project, for example, has significantly advanced scientific confidence in the practical application of integrating NAM data into read-across approaches for risk assessment (Escher et al., 2019; Moné et al., 2020). Case studies incorporating NAMs were applied and subsequently positively reviewed by international peers and programs, including the OECD IATA Case Study Project. The Horizon 2020 RISK-HUNT3R¹ project builds on the outcomes of previously funded large EU projects. The next major step is towards an NGRA of compounds with no safety information (so-called *ab initio* approach).

Through systematic and iterative evaluation of a characterized NAM toolbox and the use of case studies that address various real-life problems, the RISK-HUNT3R consortium aims to optimize the strategy to assess exposure and toxicokinetics, as well as toxicodynamics of a broad range of chemicals. The project plans to use human-relevant NAMs, some of which use novel technologies to investigate mechanisms of toxicity, to validate and implement integrated approaches to NGRA.

2 Implementing core principles of NGRA

Key characteristics of an NGRA strategy have been described repeatedly. Dent et al. (2018) gave a good summary for the cosmetics area, and RISK-HUNT3R follows nine similar principles. They may be grouped as describing the objectives, procedures,

¹ <https://www.risk-hunt3r.eu/>

Abbreviations

ADME, absorption, distribution, metabolism, and excretion; (q)AOP, (quantitative) adverse outcome pathway; DNT, developmental neurotoxicity; KE, key event; STOT, specific target organ toxicity; IATA, integrated approach to testing and assessment; MIE, molecular initiating event; NAM, new approach methodology; NGC, non-genotoxic carcinogenicity; NGRA, next-generation risk assessment; QST, quantitative system toxicology; RA, risk assessment; RISK-HUNT3R, Risk assessment of chemical integrating human centric next generation testing strategies promoting 3Rs

and documentation required for an NGRA approach (Fig. 1).

RISK-HUNT3R will implement these principles to build its testing strategy toward animal-free NGRA with a focus on three toxicological areas: specific target organ toxicity (STOT), developmental neurotoxicity (DNT), and non-genotoxic carcinogenicity (NGC). The relevance of the different test systems concerning human physiology is considered essential to provide confidence in the NGRA. The RISK-HUNT3R project addresses this notion on different levels. NGRA case studies will use already characterized state-of-the-art NAMs, which will be further optimized to model human (patho-)physiology. Additionally, using bioinformatics approaches, RISK-HUNT3R will draw from human disease-related transcriptome data in the public domain, establishing human tissue-specific gene network models overlapping those from test systems. Preservation of individual gene networks will be defined between *in vitro* test systems and human *in vivo* data, providing scientific confidence in the human relevance of *in vitro* gene networks. This knowledge will allow a direct translation of *in vitro* gene network activation to potential human adverse outcomes and will strengthen the underpinning of individual gene networks as biomarkers for key events (KEs) in AOP networks.

2.1 The RISK-HUNT3R strategy is exposure-led

Different approaches will be used to estimate exposure levels. One approach, e.g., is the use of human biomonitoring data from exposome projects and occupational data. An important strategy is the development of a human exposure framework based on internal exposure levels. This requires the application of methods that allow conversion of human external exposure data via several routes (dermal, pulmonary, oral) to concentration-time profiles within blood and organs. For this purpose, the project will, e.g., systematically determine human-relevant biotransformation and

clearance capacities in *in vitro* test systems. RISK-HUNT3R will make predictions both for parent compounds and toxicologically relevant metabolites of chemicals. Finally, toxicokinetics and toxicodynamics data derived from NAMs will be integrated into predictive systems toxicology models. A special application of the exposure framework is exposure-based waiving, analogous to the thresholds for toxicological concern (TTC) waiving concept (Hartung, 2017), but also for identifying relevant concentration ranges for testing and for defining margins of exposure.

2.2 Testing is designed to distinguish adverse effects from epiphenomenal biological perturbations.

Definition of adversity will be hypothesis-driven

The project will make use of the adverse outcome pathway (AOP) framework to implement procedures to differentiate between NAM-based predictors of adverse effects and non-relevant early adaptive and reversible changes. This is essential for hazard predictions to determine relevant point-of-departure (PoD) values. The RISK-HUNT3R project will thus make use of the extensive general knowledge of toxicity mechanisms and their link to adverse outcomes using AOPs. The project will use more than 200 AOPs currently available as models that describe the sequence of molecular and cellular events required to produce a toxic effect when an organism is exposed to a substance. A particular focus of RISK-HUNT3R is the use of reporter assays and high-throughput omics approaches to drive hypothesis formulation for AOP activation through bioinformatics analysis.

2.3 RISK-HUNT3R will integrate robust and relevant methods and include uncertainty characterization and transparent and explicit reporting

Most test systems in the RISK-HUNT3R toolbox have been extensively documented in the EU-ToxRisk project (Krebs et al.,

Box 1. Different types of uncertainties in risk assessment

As in all risk assessments, uncertainty will also be associated with an integrated NGRA framework, primarily when multiple layers of information and various data domains are used. RISK-HUNT3R will fully embrace the new scientific discipline of uncertainty assessment, addressing both aleatoric and epistemic uncertainty in NGRA.



Aleatoric uncertainty (from the Latin word *alea*, meaning "dice") arises from the inherent stochasticity of the biological and physical world, i.e. the "noise level" of test procedures. It is typically called "variability" in risk and safety assessments (see guidances by Food and Agriculture Organization, US EPA, 2011; 2014).



Epistemic uncertainty (from ancient Greek *epistēmē*, meaning 'knowledge') instead originates from imperfect knowledge. For NGRA this may refer to an insufficiently developed AOP used for an IATA.

The recent guidelines developed by EFSA on the analysis (EFSA, 2018) and the communication (EFSA, 2019) of uncertainty highlight the necessity to distinguish epistemic uncertainty from aleatoric uncertainty. Identification, characterization, and communication of uncertainties will be central to all NGRA case studies.




Fig. 2: Assessment modules of the RISK-HUNT3R NGRA strategy

RISK-HUNT3R proposes an NGRA framework composed of logical assessment elements for adequately addressing the risk associated with exposure to a target chemical. Modules cover different aspects, from identifying the exposure situations (Modules 1 and 2, green boxes) to hazard characterization (Modules 3 and 4, blue boxes). Each module is an independent element from which outcomes (data/information) are processed in Module 5 (black box) and transferred to the next module. This process may be reiterated until enough data/information is collected to perform an adequate integrated risk assessment (outward red arrow). qAOP, quantitative adverse outcome pathway; MPS, microphysiological system; PoD, point of departure; IVIVE, *in-vitro*-to-*in-vivo* extrapolation; RA, risk assessment; ADME, absorption, distribution, metabolism and excretion; WoE, weight of evidence

2020) as part of read-across case studies (Van der Stel et al., 2021; Escher et al., 2022). The innovative test systems based on either induced pluripotent stem cell (iPSC) technology or organ-on-a-chip systems developed in national and European projects, including EU-ToxRisk and in3-ITN, will be further assessed for implementation in safety testing in RISK-HUNT3R following stringent quality control. All project methods (experimental NAMs, ADME-related methods, and *in silico* models) will be documented according to a standardized OECD GD 211-compliant scheme that allows the determination of the readiness level of the method for various applications (Bal-Price et al., 2018).

Uncertainty evaluations will also be associated with the integrated NGRA framework, especially when multiple layers of information and diverse data are combined. For practical use by regulators, the output of NGRA needs to contain a characterization of the sources of uncertainty, quantitative measures of uncertainty, and a statement on confidence levels (and intervals) of the overall conclusion. RISK-HUNT3R will further develop models and methods to determine uncertainty, with the appropriate distinction between direct and indirect sources of aleatoric uncertainty (see Box 1) (Van der Bles et al., 2019; EFSA, 2018, 2019; US EPA, 2011). Qualification and quantification of uncertainty from all input levels of systems toxicology will be modelled to provide confidence in a robust risk assessment setting.

2.4 RISK-HUNT3R will use a tiered and iterative approach

The purpose and the scope of a risk assessment, as well as the depth of the analysis and thus the resources (data, tools, procedures) required for completing a risk assessment, are defined in its problem formulation phase (US EPA, 2014; Luijten et al., 2020; Solomon et al., 2016). The number of resources allocated to conducting a risk assessment should, to some extent, be determined by the level of concern, e.g., preliminary data on specific hazards or knowledge of widespread and high exposure will trigger prioritization or focused testing.

RISK-HUNT3R proposes an NGRA framework composed of logical assessment elements, essential for adequately addressing defined problems to ensure protection against human systemic health effects.

Each module is an independent element from which outcomes are processed and transferred to the next module until enough data/information is collected to perform a satisfactory risk assessment. Modules cover different steps, from identifying the exposure situations (Modules 1 and 2) to characterizing hazards (Modules 3 and 4). Establishing a non-animal, human-relevant NGRA strategy requires the systematic evaluation, iterative optimization, and alignment of *in silico* and *in vitro* tests to these four assessment modules. Information or data generated in one mod-

ule is transmitted to the overall risk assessment module for further evaluation (Module 5). In turn, Module 5 may request additional input if there is a remaining information requirement, thus allowing iterative optimization as necessary (Fig. 2).

3 The testing framework of the RISK-HUNT3R NGRA strategy

The RISK-HUNT3R project has structured its overall strategy into two sequential stages. Initially, the available methods will be tested for robustness and performance. Each element of the project toolbox will be scrutinized within relevant work packages. For this purpose, data-rich chemicals will be used so that the assay outcomes can be compared to legacy knowledge in databases. The methods that prove suitable, either directly or following optimization, will be used in the main phase of the project.

During the main stage of RISK-HUNT3R, chemicals with little or no data will be investigated in an iterative and flexible testing strategy (Fig. 3). The toxicity of a particular substance will be examined in light of a specific problem formulation. This step is crucial to determine the mandatory assessment elements, the scope of the testing strategy (e.g., the required modules), and the overall acceptable uncertainty.

The first overarching module group is focused on the determination of absorption, distribution, metabolism, and excretion (ADME) information. In Module 1, human exposure and bioavailability of the substance are evaluated after passing the barriers of first contact (skin, lung, intestine). *In vitro* models of these barrier organs will be used to establish realistic parameters for bioavailability estimation. Data will then be integrated into physiologically based kinetics (PBK) models. The possibility of metabolism leading to the formation of active and potentially toxic metabolites is often not considered in traditional *in vitro* approaches. Relevant *in vitro* models will be developed and applied in case studies to identify and quantify tissue-specific formation and the general release of these metabolites into the systemic circulation, e.g., from the liver, lung, or kidney. When necessary, toxicologically relevant stable metabolites will be synthesized and used for NAM testing. In Module 2, the RISK-HUNT3R toolbox will be applied to evaluate the metabolism, distribution, and excretion of chemicals following their systemic uptake. After each step, an exposure-based waiving principle can be used. If no relevant exposure is measured, the assessment may conclude since no further data is necessary to assess risk to human health. Alternatively, risk assessment will continue by identifying the optimal follow-up strategy: read-across, NAM-based read-across, or hazard identification and quantification steps, allowing a final integrated NGRA.

The second overarching module group applied in the latter scenario is hazard assessment (Fig. 3). The RISK-HUNT3R consortium has assembled a broad and diverse battery of screening and follow-up assays, including high-throughput *in silico* and *in vitro* technologies, to identify adverse effects of test compounds and assign them to AOP KEs. *In silico* approaches may first indicate whether chemicals will interact with cellular targets and

initiate subsequent KEs. *In vitro* assays can map critical candidate molecular initiating events (MIEs) and potential biological responses that are indicative of severe cell injury or loss of pivotal cell functions. At the next level of cell biological perturbation, high-content imaging phenotypic assays based on cell painting approaches (Delp et al., 2018; Nyffeler et al., 2020) will be implemented. For adverse cellular responses, *in vitro* multicolour reporters established in the EU-ToxRisk project that represent critical cellular stress response pathways, including oxidative stress, unfolded protein response, DNA damage response, and inflammatory signaling (Wink et al., 2014), will be used.

These data will be mapped to toxicological area-specific AOP networks to provide first indications of AOP modulation. The modular safety testing approach of RISK-HUNT3R is designed to provide alerts for most, if not all, potentially relevant adverse effects concerning STOT, DNT or NGC. It allows for some areas to take steps from qualitative to quantitative AOPs. The alert collection is assembled by capturing at least one node from each possible trajectory of the network of established qualitative AOPs (AOP-Wiki) related to these outcomes. In many cases, high-throughput omics tests will identify relevant MIEs or KEs. Complementary to this, several assays are available to capture phenotypic changes that reflect adverse outcomes. The latter strategy will be used where AOP coverage is limited but *in vitro* correlates of adverse outcomes have been identified.

A typical example is DNT, where only a few AOPs are known but good tests exist to identify disturbed neural differentiation or network function (Sachana et al., 2021). Similarly, crucial elements for an integrated approach to testing and assessment (IATA) for NGC have been identified, but the overview of AOPs relevant for NGC is not yet complete (Jacobs et al., 2020; Heu-sinkveld et al., 2020). Subsequently, for Module 4, once alerts for adversity have been generated or even when relevant AOPs have been identified by screening data from Module 3, a large panel of more advanced test systems is available. It provides further quantitative mechanistic information and, eventually, will provide evidence for the relevance and adversity of NAM data in the qAOP assessment.

Finally, in Module 5, the workflow anticipates that a complete IATA-based risk assessment is performed. This process integrates all data and quantifies overall uncertainty.

4 Current challenges for NGRA and RISK-HUNT3R innovations

RISK-HUNT3R will address several challenges towards successfully implementing NAMs in regulatory safety assessment frameworks.

Challenge 1: Integration of human-relevant biotransformation and clearance capacities into in vitro test systems

The ADME modules will systematically integrate data on human-relevant biotransformation and clearance capacities into *in vitro* test systems. Pre-systemic metabolic stability, formation, and quantification of (potentially toxic) metabolites and estimation of their release into the systemic circulation will be investi-




Fig. 3: The RISK-HUNT3R integrated approach to testing and assessment (IATA)

In RISK-HUNT3R, chemicals with little or no data will be investigated in an iterative and flexible testing strategy. The diagram shows essential features of the testing workflow and pivotal decision points to perform a full risk assessment according to the proposed testing strategy. The toxicity of a particular substance will be examined for a specific problem formulation. If no relevant exposure is measured, the assessment may conclude since no further data is necessary to assess risk to human health. Alternatively, the risk assessment will continue by identifying the optimal follow-up strategy: read-across, NAM-based read-across, or hazard identification and quantification steps, allowing a final integrated NGRA. PBK, physiologically based kinetics; HT, high-throughput; MoA, mode of action; (q)AOP, (quantitative) adverse outcome pathway; WoE, weight of evidence; NAM, new approach methodology

gated. The project will select primary human cells, organoids, or 3D tissues that mimic the *in vivo* expression and functionality of each of the three barriers (skin, lung, intestine). To identify and quantify primary metabolites, *in silico* models/tools will be used to guide the selection of relevant test compounds.

Challenge 2: Translation of high-content mode-of-action datasets into predictions of adverse outcomes

While high-content methods may be able to detect many biological perturbations triggered by unknown chemicals, it is still challenging to find out whether and which of these changes are predictive of adverse outcomes. Translation of high-content mode-of-action datasets into the prediction of adverse outcomes will be reached by combining bioinformatics and modelling approaches translating chemical effects from *in vitro* test systems to human pathology and translatable biomarkers.

Challenge 3: Establishment of qAOPs

RISK-HUNT3R will focus on transforming descriptive AOPs into qAOPs and using these as the basis for identifying safe chemical concentrations and acceptable daily intakes. RISK-HUNT3R aims to establish a framework for parameterization of qAOP networks incorporating NAM and legacy data, an essential step toward quantitative risk assessment and moving beyond mere hazard assessment.

Challenge 4: Integration of NAM data in predictive systems toxicology models

Toxicokinetics and toxicodynamics NAM data and partial computational models will be integrated into predictive quantitative systems toxicology (QST) models. QST models complement quantitative systems pharmacology models, incorporating toxicokinetics with mechanistic models of physiological, pharma-

cological, and toxicological mechanisms. QST models for predicting adverse outcomes in humans will integrate multi-tiered biological information, including quantitative knowledge of toxicokinetics, physiology, and baseline function at the level of the cell/tissue/organ system, toxicity mechanisms, and dynamics of injury biomarkers and endpoints (Bloomingdale et al., 2017).

Challenge 5: Quantification of uncertainties in overall risk assessment

The qualification and quantification of uncertainties will be addressed in the project concerning all input levels of systems toxicology models to provide confidence in a robust risk assessment setting. The transparent weighting of and reporting on uncertainties will be key in guiding the final assessment.

5 Impact of RISK-HUNT3R

The RISK-HUNT3R consortium has put together a multi-stakeholder and multi-expert team. Input from the different perspectives of academia, industry, and regulatory agencies will be used to build confidence and trust that the new strategies are fit-for-purpose and collect essential input. Additionally, a structured dissemination plan will assure a continuous dialogue with the stakeholder community. The impact on non-animal chemical risk assessment will be enhanced by RISK-HUNT3R participation in the ASPIS² (Animal-free safety assessment of chemicals: project cluster for implementation of novel strategies) cluster, teaming up with the two adjacent and complimentary Horizon 2020 projects ONTOX³ and PrecisionTOX⁴. The goal is to ensure optimal conditions, in terms of regulatory and commercial objectives, for sustainable use of *in vitro* and *in silico* methods and non-animal safety assessment strategies. NAM-based NGRA will apply to multiple regulatory contexts across industry sectors. Its goal is to protect different population subgroups (distinguished by, e.g., exposure situation, age, or gender). The broader scope also includes the more vulnerable groups, such as children, pregnant women, and the elderly. Toxicokinetic modelling and the consideration of biological factors affecting hazard (e.g., via gene expression variations) will include the relevant variables and their input factors.

References

- Bal-Price, A., Hogberg, H. T., Crofton, K. M. et al. (2018). Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. *ALTEX* 35, 306-352. doi:10.14573/altex.1712081
- Bloomingdale, P., Housand, C., Apgar, J. F. et al. (2017). Quantitative systems toxicology. *Curr Opin Toxicol* 4, 79-87. doi:10.1016/j.cotox.2017.07.003
- Busquet, F., Kleensang, A., Rovida, C. et al. (2020). New European Union statistics on laboratory animal use – What really counts! *ALTEX* 37, 167-186. doi:10.14573/altex.2003241
- Delp, J., Gutbier, S., Klima, S. et al. (2018). A high-throughput approach to identify specific neurotoxicants/ developmental toxicants in human neuronal cell function assays. *ALTEX* 35, 235-253. doi:10.14573/altex.1712182
- Dent, M., Amaral, R. T., Da Silva, P. A. et al. (2018). Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients. *Comput Toxicol* 7, 20-26. doi:10.1016/j.comtox.2018.06.001
- EFSA (2018). Guidance on Uncertainty Analysis in Scientific Assessments. *EFSA J* 16, e05123. doi:10.2903/j.efsa.2018.5123
- EFSA (2019). Guidance on Communication of Uncertainty in Scientific Assessments. *EFSA J* 17, e05520. doi:10.2903/j.efsa.2019.5520
- Ennever, F. K. and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. *Regul Toxicol Pharmacol* 38, 52-57. doi:10.1016/s0273-2300(03)00068-0
- Escher, S. E., Kamp, H., Bennekou, S. H. et al. (2019). Towards grouping concepts based on new approach methodologies in chemical hazard assessment: The read-across approach of the EU-ToxRisk project. *Arch Toxicol* 93, 3643-3667. doi:10.1007/s00204-019-02591-7
- Escher, S. E., Aguayo-Orozco, A., Benfenati, E. et al. (2022). Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action. *Toxicol In Vitro* 79, 105269. doi:10.1016/j.tiv.2021.105269
- Hartung, T. and Leist, M. (2008). Food for thought ... on the evolution of toxicology and the phasing out of animal testing. *ALTEX* 25, 91-102. doi:10.14573/altex.2008.2.91
- Hartung, T. (2009). Toxicology for the twenty-first century. *Nature* 460, 208-212. doi:10.1038/460208a
- Hartung, T. (2017). Thresholds of toxicological concern – Setting a threshold for testing below which there is little concern. *ALTEX* 34, 331-351. doi:10.14573/altex.1707011
- Heusinkveld, H., Braakhuis, H., Gommans, R. et al. (2020). Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals. *Crit Rev Toxicol* 50, 725-739. doi:10.1080/10408444.2020.1841732
- Jacobs, M. N., Colacci, A., Corvi, R. et al. (2020). Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens. *Arch Toxicol* 94, 2899-2923. doi:10.1007/s00204-020-02784-5
- Krebs, A., van Vugt-Lussenburg, B. M. A., Waldmann, T. et al. (2020). The EU-ToxRisk method documentation, data process-

² <https://aspis-cluster.eu/>

³ <https://ontox-project.eu/>

⁴ <https://precisiontox.org/>



- ing and chemical testing pipeline for the regulatory use of new approach methods. *Arch Toxicol* 94, 2435-2461. doi:10.1007/s00204-020-02802-6
- Krewski, D., Andersen, M. E., Tyshenko, M. G. et al. (2020). Toxicity testing in the 21st century: Progress in the past decade and future perspectives. *Arch Toxicol* 94, 1-58. doi:10.1007/s00204-019-02613-4
- Leist, M., Hartung, T. and Nicotera, P. (2008). The dawning of a new age of toxicology. *ALTEX* 25, 103-114. doi:10.14573/altex.2008.2.103
- Leist, M. and Hartung, T. (2013). Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. *Arch Toxicol* 87, 563-567. doi:10.1007/s00204-013-1038-0
- Luijten, M., Rorije, E., Sprong, R. C. et al. (2020). Practical application of next generation risk assessment of chemicals for human health. *Chem Res Toxicol* 33, 693-694. doi:10.1021/acs.chemrestox.0c00074
- Moné, M. J., Pallocca, G., Escher, S. E. et al. (2020). Setting the stage for next-generation risk assessment with non-animal approaches: The EU-ToxRisk project experience. *Arch Toxicol* 94, 3581-3592. doi:10.1007/s00204-020-02866-4
- NRC – National Research Council (2007). *Toxicity Testing in the 21st Century: A Vision and a Strategy*. Washington, DC, USA: The National Academies Press. doi:10.17226/11970
- Nyffeler, J., Willis, C., Lougee, R. et al. (2020). Bioactivity screening of environmental chemicals using imaging-based high-throughput phenotypic profiling. *Toxicol Appl Pharmacol* 389, 114876. doi:10.1016/j.taap.2019.114876
- Sachana, M., Willett, C., Pistollato, F. et al. (2021). The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays. *Reprod Toxicol* 103, 159-170. doi:10.1016/j.reprotox.2021.06.006
- Solomon, K. R., Wilks, M. F., Bachman, A. et al. (2016). Probable formulation for risk assessment of combined exposures to chemicals and other stressors in humans. *Crit Rev Toxicol* 46, 835-844. doi:10.1080/10408444.2016.1211617
- US EPA (2011). *Exposure Factors Handbook (Final Report)*. U.S. Environmental Protection Agency, Washington, DC. EPA/600/R-09/052F
- US EPA (2014). *Framework for human health risk assessment to inform decision making*. U.S. Environmental Protection Agency, Washington, DC. EPA/100/R-14/001
- Van der Bles, A. M., van der Linden, S., Freeman, A. L. J. et al. (2019). Communicating uncertainty about facts, numbers and science. *R Soc Open Sci* 6, 181870. doi:10.1098/rsos.181870
- Van der Stel, W., Carta, G., Eakins, J. et al. (2021). New approach methods (NAMs) supporting read-across: Two neurotoxicity AOP-based IATA case studies. *ALTEX* 38, 615-635. doi:10.14573/altex.2103051
- Weaver, R. J., Blomme, E. A., Chadwick, A. E. et al. (2020). Managing the challenge of drug-induced liver injury: A roadmap for the development and deployment of preclinical predictive models. *Nat Rev Drug Discov* 19, 131-148. doi:10.1038/s41573-019-0048-x
- Wink, S., Hiemstra, S., Huppelschoten, S. et al. (2014). Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. *Chem Res Toxicol* 27, 338-355. doi:10.1021/tx4004038

Conflict of interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).